Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant chewable tablet in pediatric asthma
NCT03650400Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fevipiprant in asthma, sponsored by Novartis. Started May 2019; status: terminated.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03650400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650400.